1 results match your criteria: "MedStar Washington Hospital CenterMedStar Health Research InstituteDepartment of RadiologyMedStar Washington Hospital Center[Affiliation]"
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Eur J Endocrinol
March 2016
Division of EndocrinologyDepartment of Medicine, MedStar Washington Hospital CenterMedStar Health Research InstituteDepartment of RadiologyMedStar Washington Hospital Center, 110 Irving Street Northwest, Washington, District of Columbia 20010, USA.
Objective: Our objective was to evaluate the efficacy and safety of sunitinib following at least one course of radioactive iodine treatment in patients with advanced differentiated thyroid cancer (DTC). The study endpoints included best response rate (including best objective response rate) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, measurement of serum thyroglobulin (Tg), and toxicity evaluation.
View Article and Find Full Text PDF